FAP 억제제 : 시장 규모, 대상 환자층, 경쟁 구도 및 시장 예측(2040년)

Key Highlights:

• FAP is highly expressed in several solid tumors while remaining limited in most healthy tissues, offering an attractive therapeutic window. Inhibition of FAP is expected to reduce matrix remodeling, modulate immunosuppressive signalling, and potentially enhance the penetration and efficacy of anticancer therapies.
• The landscape also benefits from advances in FAP-targeted imaging agents, which can noninvasively map FAP expression and potentially guide therapeutic decision-making. These diagnostic tools improve the ability to assess target engagement, refine response assessment, and support adaptive trial designs that incorporate real-time biological feedback.
• Emerging FAP inhibitors include agents such as AZD2389 and BXCL701, both of which are progressing through early-phase clinical evaluation and aim to leverage improved selectivity and more favorable pharmacologic profiles. These candidates highlight the next generation of approaches focused on stronger tumor microenvironment modulation with the potential to enhance combination therapy outcomes.

DelveInsight's "FAP Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2040" report delivers an in-depth understanding of FAP Inhibitor, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The FAP Inhibitor market report provides insights around existing treatment practices in patients with FAP Inhibitor, approved (if any) and emerging FAP Inhibitor, market share of individual therapies, patient pool eligible for treatment with FAP Inhibitor, along with current and forecasted 7MM FAP Inhibitor market size from 2022-2040 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new FAP Inhibitor in different geographies, along with insights on FAP Inhibitor pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2022-2040

FAP Inhibitor Overview

Fibroblast activation protein (FAP) inhibitors represent an expanding therapeutic class targeting FAP-expressing cancer-associated fibroblasts, which contribute to tumor growth, immune evasion, and stromal remodeling. Their development stems from increasing recognition of the tumor microenvironment as a driver of resistance to conventional and immunologic therapies. By selectively inhibiting FAP activity, these agents aim to disrupt the supportive stromal architecture that enables tumor progression.

Target Patient Pool Analysis

• The SEER database estimates approximately 22,010 new cases of Acute Myeloid Leukemia are expected in 2025 in the US, reflecting the continued clinical and epidemiologic burden of this aggressive hematologic malignancy.
• According to the SEER database, approximately 67,440 new pancreatic cancer cases are expected in 2025 in the US, out of which an estimated 51% have metastasized, highlighting the substantial burden of advanced disease within this population.
• About 93% of pancreatic cancers are exocrine tumors, the most common being pancreatic ductal adenocarcinoma, while the remaining ~7% are neuroendocrine (islet) tumors, which generally grow more slowly.
• In pancreatic ductal adenocarcinoma, the liver is by far the most frequent site of metastasis (>60% of patients), followed by lungs and peritoneum (~30%), and about 10% of cases metastasize to bone or adrenal glands.

FAP Inhibitor Drug Chapters

The drug chapter segment of the FAP Inhibitor report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the FAP Inhibitor clinical trial details, pharmacological action, agreements and collaborations related to FAP Inhibitor, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

FAP Inhibitor Emerging Drugs

AZD2389: AstraZeneca

AZD2389 is an innovative, oral small-molecule inhibitor developed by AstraZeneca to target Fibroblast Activation Protein (FAP), a key driver in the progression of tissue scarring. The drug is specifically designed for metabolic dysfunction-associated steatohepatitis (MASH) and chronic liver fibrosis. It utilizes a unique covalent binding mechanism that ensures high selectivity and strong attachment to the target protein, minimizing off-target effects. Following successful Phase I trials that proved its safety and predictable behavior in the body, it is currently in Phase IIa clinical studies. These studies are evaluating its ability to improve liver biomarkers and halt fibrotic activity in patients with compensated cirrhosis, with critical data readouts expected later this year.

BXCL701: OnkosXcel Therapeutics (a subsidiary of BioXcel Therapeutics)

BXCL701, developed by OnkosXcel Therapeutics, is a potent FAP inhibitor designed to revolutionize cancer treatment by activating the body's own immune system. Its primary function is to trigger inflammation within the tumor environment, effectively converting "cold" tumors-which usually hide from the immune system-into "hot" tumors that are easily recognized and attacked. The drug is being tested across a wide range of aggressive cancers, including Metastatic Pancreatic Cancer, AML, and Prostate Cancer. Due to its high potential in areas with few treatment options, the US FDA has granted it multiple Orphan Drug Designations and a Fast Track Designation. With a clinical foundation built on data from over 800 subjects, BXCL701 represents a significant emerging candidate in the FAP-targeted oncology landscape.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on FAP Inhibitor as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of FAP Inhibitor, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

FAP Inhibitor Market Outlook

This section will include details on changing FAP Inhibitor market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

FAP Inhibitor Drugs Uptake

This section focuses on the uptake rate of potential FAP Inhibitor already launched and expected to be launched in the market during 2022-2040, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

FAP Inhibitor Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

FAP Inhibitor Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for FAP Inhibitor.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on FAP Inhibitor' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on FAP Inhibitor addressable patient pool
• A detailed review of the FAP Inhibitor market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM FAP Inhibitor market.
• Market Size of Inhibitors by therapies and indication will be provided

FAP Inhibitor Report Key Strengths

• 15 Years FAP Inhibitor Market Forecast
• The 7MM Coverage
• FAP Inhibitor Competitive Landscape of current and emerging therapies
• FAP Inhibitor Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician's perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• FAP Inhibitor Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs:

• What was the FAP Inhibitor total market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like by 2040? What are the contributing factors for FAP Inhibitor market growth?
• Which drug is going to be the largest contributor by 2040?
• What is the market access and reimbursement scenario of FAP Inhibitor?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the FAP Inhibitor Market.
• Understand the existing FAP Inhibitor market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of FAP Inhibitor

4. Key Events

5. FAP Inhibitor Market Overview At A Glance

• 5.1. Market Share (%) Distribution of FAP Inhibitor By Therapy in 2025
• 5.2. Market Share (%) Distribution of FAP Inhibitor By Therapy in 2040

6. Background And Overview

7. Target Population

8. FAP Inhibitor Marketed Drugs

• 8.1. Key Competitors
  • 8.1.1. Product Description
  • 8.1.2. Regulatory Milestones
  • 8.1.3. Other Developmental Activities
  • 8.1.4. Ongoing Clinical Development
  • 8.1.5. Safety and Efficacy

9. FAP Inhibitor Emerging Drugs

• 9.1. Key Competitors
  • 9.1.1. Product Description
  • 9.1.2. Other Development Activities
  • 9.1.3. Clinical Development
    • 9.1.3.1. Clinical Trials Information
  • 9.1.4. Safety and Efficacy

10. FAP Inhibitor: The 7MM Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Key Market Forecast Assumptions
• 10.4. Total Market Size of FAP Inhibitor in the 7MM
  • 10.4.1. Market Size of FAP Inhibitor By Therapies In the 7MM
  • 10.4.2. Market Size of FAP Inhibitor By Indication In the 7MM
• 10.6. United States Market
  • 10.6.1. Total Market Size of FAP Inhibitor in the United States
  • 10.6.2. Market Size of FAP Inhibitor By Therapies in the United States
• 10.7. EU4 and the UK Market
  • 10.7.1. Total Market Size of FAP Inhibitor in EU4 and the UK
  • 10.7.2. Market Size of FAP Inhibitor By Therapies in EU4 and the UK
• 10.8. Japan Market
  • 10.8.1. Total Market Size of FAP Inhibitor in Japan
  • 10.8.2. Market Size of FAP Inhibitor By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

• 14.1. United States
  • 14.1.1. Centre for Medicare & Medicaid Services (CMS)
• 14.2. EU4 and the UK
  • 14.2.1. Germany
  • 14.2.2. France
  • 14.2.3. Italy
  • 14.2.4. Spain
  • 14.2.5. United Kingdom
• 14.3. Japan
  • 14.3.1. MHLW

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight